9902891-2
IB03 Comm

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 207/34, 231/14, 233/90, 249/06, 257/04, A61K 31/40, 31/41, C07D 401/12, 403/12, 409/12, 413/12

A1

(11) International Publication Number: **WO 98/28269**

(43) International Publication Date: 2 July 1998 (02.07.98)

(21) International Application Number: PCT/US97/22895

(22) International Filing Date: 15 December 1997 (15.12.97)

(30) Priority Data:

08/769,859	23 December 1996 (23.12.96)	US
08/879,944	20 June 1997 (20.06.97)	US

(71) Applicant: THE DUPONT MERCK PHARMACEUTICAL COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).


(72) Inventors: PINTO, Donald, Joseph, Phillip; 39 Whitson Road, Newark, DE 19702 (US). PRUITT, James, Russell; 237 Skycrest Drive, Landenberg, PA 19350 (US). CACCIOLA, Joseph; 105 Pattie Drive, Newark, DE 19702 (US). FEVIG, John, Matthew; 291 Church Road, Lincoln University, PA 19352 (US). HAN, Qi; 2609 Marhill Drive, Wilmington, DE 19810 (US). ORWAT, Michael, James; 118 South Colts Neck Way, Hockessin, DE 19707 (US). QUAN, Mimi, Lifen; 113 Venus Drive, Newark, DE 19711 (US). ROSSI, Karen, Anita; 120A Emery Court, Newark, DE 19711 (US).

(74) Agent: VANCE, David, H.; The Dupont Merck Pharmaceutical Company, Legal/Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(81) Designated States: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS



(I)

(57) Abstract

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula (I) or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D may be $C(=NH)NH_2$, which are useful as inhibitors of factor Xa.